Targeting Protein Kinases Degradation by PROTACs

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Kinase dysregulation drives cancer progression, making kinases crucial therapeutic targets.
• Traditional kinase inhibitors face challenges like resistance and limited efficacy against complex proteins.
• Next-generation therapies are needed to overcome limitations of current anticancer drugs.

Purpose of the Study:

• To review recent progress in proteolysis targeting chimeras (PROTACs) for targeting kinases in cancer therapy.
• To focus on novel chemical entities and medicinal chemistry aspects of kinase-targeting PROTACs.

Main Methods:

• Literature review of recent advancements in PROTAC technology.
• Focus on PROTACs designed to target various kinases.
• Analysis of new chemical entities in medicinal chemistry for PROTAC development.

Main Results:

• PROTACs represent a promising strategy for targeted protein degradation via the ubiquitin-proteasome pathway.
• Recent studies show significant progress in developing PROTACs against diverse kinase targets.
• Novel chemical entities are expanding the scope and efficacy of kinase-targeting PROTACs.

Conclusions:

• PROTAC technology offers a powerful alternative to traditional kinase inhibitors for cancer treatment.
• Targeted protein degradation by PROTACs overcomes key limitations of current kinase-targeted therapies.
• Continued medicinal chemistry efforts are vital for advancing PROTAC-based anticancer drug development.